A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)

被引：0
|
作者：
Oh, Stephen [1 ]
Kiladjian, Jean-Jacques [2 ]
Palandri, Francesca [3 ]
Gotlib, Jason [4 ]
Mohan, Sanjay [5 ]
Ali, Haris [6 ]
Asatiani, Ekatherine [7 ]
Seguy, Francis [7 ]
Zhou, Feng [8 ]
Verstovsek, Srdan [9 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] Univ Paris, INSERM, Hop St Louis, AP HP, Paris, France
[3] Azienda Osped Univ Bologna, IRCCS Ist Ricovero & Cura Carattere Sci, Policlin S Orsola Malpighi, Bologna, Italy
[4] Stanford Canc Inst, Stanford, CA USA
[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[6] City Hope Med Ctr, Duarte, CA USA
[7] Incyte Biosci Int Sarl, Morges, Switzerland
[8] Incyte Corp, Wilmington, DE USA
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH2021-PO
引用
收藏
页码：111 / 112
页数：2
相关论文
共 50 条
  • [1] A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)
    Oh, Stephen T.
    Gotlib, Jason
    Mohan, Sanjay
    Ali, Haris
    Asatiani, Ekatherine
    Seguy, Francis
    Zhou, Feng
    Verstovsek, Srdan
    BLOOD, 2020, 136
  • [2] A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104).
    Oh, Stephen T.
    Kiladjian, Jean-Jacques
    Palandri, Francesca
    Gotlib, Jason R.
    Mohan, Sanjay
    Ali, Haris
    Asatiani, Ekatherine
    Seguy, Francis
    Zhou, Feng
    Verstovsek, Srdan
    CANCER RESEARCH, 2021, 81 (13)
  • [3] A Phase 1/2 Study of INCB000928 As Monotherapy or Combined with Ruxolitinib (RUX) in Patients (Pts) with Anemia Due to Myelofibrosis (MF)
    Mohan, Sanjay R.
    Oh, Stephen T.
    Ali, Haris
    Hunter, Anthony M.
    Palandri, Francesca
    Lamothe, Betty
    Cui, Yi
    Seguy, Francis
    McBride, Amanda
    Savona, Michael Robert
    Kiladjian, Jean-Jacques
    Verstovsek, Srdan
    BLOOD, 2022, 140 : 3943 - 3944
  • [4] Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis
    Mohan, Sanjay
    Oh, Stephen
    Kiladjian, Jean-Jacques
    Takeuchi, Masahiro
    Gotlib, Jason
    Ritchie, Ellen K.
    Shimomura, Taizo
    Guglielmelli, Paola
    Hunter, Anthony M.
    Palandri, Francesca
    Boyer, Francoise
    Rambaldi, Alessandro
    Mori, Takehiko
    Ito, Tomoki
    Lamothe, Betty
    Yang, Yan-Ou
    Cui, Yi
    Seguy, Francis
    McBride, Amanda
    Bose, Prithviraj
    BLOOD, 2023, 142
  • [5] Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF).
    Bose, Prithviraj
    Mohan, Sanjay
    Oh, Stephen
    Gotlib, Jason R.
    Ritchie, Ellen K.
    Shimomura, Taizo
    Ali, Haris
    Boyer, Francoise
    Guglielmelli, Paola
    Hunter, Anthony
    Lamothe, Betty
    Cui, Yi
    Seguy, Francis
    McBride, Amanda
    Palandri, Francesca
    Takeuchi, Masahiro
    Kiladjian, Jean-Jacques
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Phase I/II Study of the Activin Receptor-Like Kinase 2 (ALK2) Inhibitor Zilurgisertib (INCB000928, LIMBER-104) as Monotherapy or With Ruxolitinib in Patients With Anemia Due to Myelofibrosis
    Bose, Prithviraj
    Mohan, Sanjay
    Oh, Stephen
    Gotlib, Jason
    Ritchie, Ellen
    Shimomura, Taizo
    Ali, Haris
    Boyer, Francoise
    Guglielmelli, Paola
    Hunter, Anthony
    Lamothe, Betty
    Cui, Yi
    Seguy, Francis
    McBride, Amanda
    Palandri, Francesca
    Takeuchi, Masahiro
    Kiladjian, Jean-Jacques
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S401 - S402
  • [7] A Phase 2 Study of the Safety and Efficacy of INCB050465 in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)
    Daver, Naval
    Dao, Kim-Hien
    Assad, Albert
    Verstovsek, Srdan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S351 - S351
  • [8] A Phase 1 Study of INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis (INCB 57643-103)
    Lihou, Christine
    Zhou, Gongfu
    Zheng, Fred
    BLOOD, 2020, 136
  • [9] A phase 1 study of INCB057643 monotherapy in patients with relapsed or refractory myelofibrosis (INCB 57643-103)
    Vachhani, Pankit
    Lihou, Christine
    Zhou, Gongfu
    Zheng, Fred
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 112 - 112
  • [10] A Phase 1 Study of INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis (INCB 57643-103).
    Vachhani, Pankit
    Lihou, Christine
    Zhou, Gongfu
    Zheng, Fred
    CANCER RESEARCH, 2021, 81 (13)
12345